enzh-TWfrdeitjaptrues

The 10th International Workshop for Waldenstrom's Macroglobulinemia was held from October 11th through the 13th, 2018 in New York City. The venue chosen for this meeting is one of New York City’s premier hotels, the New York Marriott Downtown Hotel and Conference center, situated in Lower Manhattan near Battery Park. The hotel nestles in one of the city’s most historic areas near Wall Street, the 9/11 Memorial Museum and One World Observatory. Onsite registration and check-in began at 12:00 on Wednesday, October 10th, conference sessions starting on Thursday, the 11th, at 7:30am. Overall, IWWM-10 included 16 sessions with 73 technical presentations including a Junior Investigator Poster presentation event with 5 short oral presentations, 79 WM-related posters, 8 "Keynote" lectures, Opening and Closing Ceremonies with associated award presentations, a Faculty Reception, 5 panel discussions on treatment approaches to WM, and 3 consensus panel discussions.

 

The Opening Ceremonies were held on Thursday, October 11 at Ellis Island, where the delegates were treated to a self-tour of the museum and walking exhibits. After a welcome by the IWWM-10 chairs (Jorge Castillo, Lia Palomba and Richard Furman), the keynote address was given by Ken Anderson, followed by the IWMF's President's address by Carl Harrington. Presentation of the Young Investigator awards was given by Meletios Dimopoulos and Veronique Leblond to the following YIA Recipients. Dinner was served upstairs in the beautiful Ellis Island function hall.

On Friday, October 12, the poster session was held from 5-6:00pm in the Marriott Financial Ballroom where 79 posters were presented for viewing and discussion. 5 posters were selected for short oral presentations by L. Brandefors, I. Defrancesco. L. Arcaini, A. Paulus, and R. DeTute. After the poster session, the Faculty Delegates were treated to dinner at the Pier A Harbor House, where the Robert A. Kyle award was presented to Giampaolo Merlini.

 

The Closing Ceremonies were held the evening of October 13 at the United Nations Delegates Dining Room. After a tour of the General Assembly and Security Council chambers, the Delegates were treated to the Chairs' Welcome, followed by a keynote address from Anders Waldenstrom, MD, PhD (and son of Jan Waldenstrom). Frank Wollheim, MD, PhD and former student of Jan Waldenstrom gave a wonderful talk about his recollections from the time spent with his mentor, as well as the friendship between Jan Waldenstrom and Dag Hammaskjold (UN Sec. General 1953-61). The 2018 Jan Gosta Waldenstrom Award was given to Bart Barlogie. This was followed by a keynote address by Thomas Cavanaugh, president of Janssen Oncology (one of the sponsors of the event). This was followed by the presentation of the Peter S. Bing Humanitarian Awards, which were presented to Carl Harrington, Ranjana Advani, Morton Coleman, and Christopher Patterson.

The 2018 IWWM-10 was our most comprehensive meeting to date, and we expect future workshops to continue its ideology to build on this progress. These meetings reflect the continued growth in investigators working on the genetic basis, pathogenesis, and clinical treatments of WM. Since the IWWM began in 2000, the number of international participating investigators has steadily grown as have the number of WM related publications including those created and developed from the IWWM Workshops. Such publications have been the New England Journal of Medicine, Blood, Clinical Lymphoma Myeloma, Haematologica, Journal of Clinical Oncology, and Seminars of Oncology.

IWWM-10 continues the mission to enrich each attendee’s understanding and help foster discoveries and collaborations leading to more effective treatments and ultimately find a cure for Waldenstrom's macroglobulinemia.

For more information, including program agenda, abstracts, and photos, please visit http://wmworkshop.org/conferences/new-york-2018

Chair Organizers:

Jorge Castillo, MD (Dana-Farber Cancer Institute)
Richard Furman, MD (Weill Cornell Medicine, Cornell University)
M. Lia Palomba, MD (Memorial Sloan Kettering Cancer Institute)
Steven Treon, MD, PhD (Dana-Farber Cancer Institute)

Latest Bing Center News

WM and COVID-19: WMUK Webinar Recordings

WM and COVID-19: WMUK Webinar Recordings

On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).

Read more..

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

Read more..

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...

Read more..

COVID-19 & Hematologic Malignancies: Patient Experience Update

COVID-19 & Hematologic Malignancies: Patient Experience Update

We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.

Read more..

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Read more..

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.

Read more..

ASCO 2020 Virtual Meeting

ASCO 2020 Virtual Meeting

ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online.  As in the past, they provide abstracts online via the conference website.  The scientific program will take place May 29 through May 31.

Read more..

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..

Waldenström Macroglobulinemia Specialty Channel

Waldenström Macroglobulinemia Specialty Channel

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Read more..